Immune System News and Research

RSS

Specific forms of lymphoma create their own survival niche

Cancer cells do not grow equally well everywhere in the body. Often, they first create the conditions in which they can grow. Many years ago researchers discovered that solid tumors attract blood vessels to ensure their supply of nutrients by secreting specific factors.

7 Jun 2011

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline.

7 Jun 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004.

7 Jun 2011

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline (GSK). This collaboration is aimed at developing a second-generation vaccine against malaria—a deadly disease that kills close to 800,000 people annually, most of them young children under age five in Africa. MVI drives the development of malaria vaccines by joining its scientific, managerial, and field expertise with companies, universities, and governments to test potential malaria vaccines and invest in those with the most promise.

6 Jun 2011

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab’s capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

6 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

An anniversary — AIDS turns 30

Three decades after the first cases of AIDS were recorded, more than 60 million people have been infected worldwide. Scientists agree that the epidemic is far from over and, even with major treatment advances and improvement in understanding the illness, hurdles remain in the effort to eradicate the disease.

6 Jun 2011

First Edition: June 6, 2011

Kaiser Health News staff writer Christopher Weaver reports: "Short on cash and time, officials in California and at least a dozen other states have turned to philanthropies to help pay for the extra work required under the federal health law".

6 Jun 2011

New gene therapy may cure Type 1 diabetes

An experimental cure for Type 1 diabetes has a nearly 80 percent success rate in curing diabetic mice. The results, to be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston, offer possible hope of curing a disease that affects 3 million Americans.

6 Jun 2011

Super microscopes help scientists identify exact molecular 'switch' that spurs T-cells into action

Using the only microscope of its kind in Australia, medical scientists have been able for the first time to see the inner workings of T-cells, the front-line troops that alert our immune system to go on the defensive against germs and other invaders in our bloodstream.

6 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

ImaginAb, GE Healthcare sign master research deal to develop new PET diagnostic imaging agents

GE Healthcare Ltd. and ImaginAb, Inc. have executed a master research agreement around the development of new PET (Positron Emission Tomography) diagnostic imaging agents based on ImaginAb's antibody fragment technology. The agreement is launched with an initial exclusive collaboration around a novel cardiovascular target.

6 Jun 2011

Anti-ghrelin vaccine decreases food intake and increases calorie burning in mice

A new therapeutic vaccine to treat obesity by suppressing the appetite-stimulating hormone ghrelin decreases food intake and increases calorie burning in mice, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

New skin cancer drug brings hope

A new drug for the dreaded cancer melanoma is in the horizon. It is called Vemurafenib. This is a class of drug that cancer researchers are applauding today at the American Society of Clinical Oncology's annual meeting in Chicago.

5 Jun 2011

Scientists use super microscope to pinpoint body’s immunity ‘switch’

5 Jun 2011

DFG to form new collaborative research centers as of 1 July 2011

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish 21 new Collaborative Research Centres (CRCs) as of 1 July 2011. This was decided by the relevant Grants Committee at its spring meeting in Bonn.

4 Jun 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.

4 Jun 2011

GW researchers demonstrate Mta1 gene's role in survival of schistosomes

By using mice lacking a crucial gene that controls the process of chromatin remodeling of cytokines including those responsible for inflammation and comparing them to normal wild type mice with the gene, researchers at the George Washington University School of Medicine and Health Sciences have shown that the gene, Mta1, is essential for the parasite Schistosoma haematobium to establish a productive infection and survival in the host.

4 Jun 2011

Dendritic cells secrete signal molecule that contributes to pathogenesis of atherosclerosis

Atherosclerosis is the most common cause of cardiovascular disease, and results from chronic inflammation of arterial vessel walls. An international collaboration led by Professor Christian Weber of Ludwig-Maximilians-Universität (LMU) in Munich and Privatdozentin Alma Zernecke of Würzburg University now shows that dendritic cells stimulate this process by derailing a mechanism that normally acts as a brake on immune reactions.

4 Jun 2011

Immune System News and Research

Specific forms of lymphoma create their own survival niche

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

An anniversary — AIDS turns 30

First Edition: June 6, 2011

New gene therapy may cure Type 1 diabetes

Super microscopes help scientists identify exact molecular 'switch' that spurs T-cells into action

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

ImaginAb, GE Healthcare sign master research deal to develop new PET diagnostic imaging agents

Anti-ghrelin vaccine decreases food intake and increases calorie burning in mice

New skin cancer drug brings hope

Scientists use super microscope to pinpoint body’s immunity ‘switch’

DFG to form new collaborative research centers as of 1 July 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

GW researchers demonstrate Mta1 gene's role in survival of schistosomes

Dendritic cells secrete signal molecule that contributes to pathogenesis of atherosclerosis

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News